Strengths

IRIX’s current ratio of 1.82 and quick ratio of 1.08 indicate near-term liquidity above many smaller medtech peers, supporting operating flexibility.

Net debt to EBITDA of 0.39 suggests limited leverage versus more indebted device peers, reducing refinancing pressure and preserving balance-sheet optionality.

The company’s cash conversion cycle of 84.6 days is manageable for a specialized medical-device business, though it remains less efficient than best-in-class peers.

Despite negative ROIC of -19.5%, the niche product focus can still support differentiated positioning if execution improves relative to broader, lower-margin competitors.

Weaknesses

ROIC of -19.5% shows capital is not earning its cost, leaving IRIX structurally weaker than profitable medtech peers with positive returns.

Debt to equity of 1.10 is elevated for a small-cap device company, constraining financial flexibility versus peers with cleaner capital structures.

A cash conversion cycle of 84.6 days ties up working capital longer than efficient peers, limiting reinvestment capacity and margin resilience.

The absence of disclosed operating and gross margin data in the provided metrics limits evidence of competitive efficiency, but the negative ROIC still signals weak economics.

Opportunities

If IRIX improves working-capital discipline, its 1.08 quick ratio provides a base to convert liquidity into faster inventory and receivables turnover than peers.

Lower leverage than many peers creates room to fund commercialization or product development without immediate balance-sheet stress.

Any sustained improvement from negative ROIC toward positive returns would materially narrow the gap with stronger medtech peers and improve structural positioning.

The company’s current liquidity profile can support selective execution improvements, which matter more in niche device markets than in scale-driven diversified peers.

Threats

Persistent negative ROIC threatens long-term competitiveness because peers with positive capital returns can reinvest faster and compound market share.

A 84.6-day cash conversion cycle increases exposure to inventory and receivables shocks, especially versus peers with tighter operating cycles.

Higher debt-to-equity than many established device peers raises vulnerability if earnings remain weak, because financing costs can absorb scarce cash generation.

Without evidence of durable margin strength, IRIX remains exposed to larger peers with greater scale, purchasing power, and commercialization efficiency.

Overall Score

IRIX’s balance sheet is serviceable, but negative capital returns and weak working-capital efficiency leave it structurally behind stronger medtech peers.